FDA Fast Track: The Designation Doesn't Buy Rolling Review

Fast Track designation under Section 506(b) of the FD&C Act runs on the lowest evidence bar of FDA's four expedited programs: nonclinical or clinical data showing the potential to address an unmet medical need in a serious condition. Sponsors that clear that bar often assume the harder part is done, then discover that Rolling Review — the benefit they actually wanted — is a second approval they still have to earn.

What Fast Track actually tests

The qualifying question is narrower than sponsors often assume: does the drug treat a serious condition, and does the available nonclinical or clinical data show potential to address an unmet medical need. That is a lower threshold than the standard behind our RMAT coverage, where FDA requires preliminary clinical evidence that the product has the potential to address an unmet need in a way existing therapy does not. Fast Track does not require preliminary clinical evidence at all — nonclinical data demonstrating the drug's potential can be enough to request it, which is also why it is typically the first expedited designation a sponsor pursues inside an IND program, well before a Breakthrough or RMAT case can be made.

Two sections, two approvals

Section 506(b) and Section 506(c) are adjacent in the statute and easy to read as one benefit. They are not. Designation under 506(b) makes a sponsor eligible for Rolling Review; it does not activate it. To actually submit an NDA or BLA in pieces, the sponsor must separately propose a schedule for completing the remaining sections, and FDA has to determine that schedule is acceptable before review of the earlier sections begins at all.

1. Earn Fast Track first. File the request on the unmet-need case once nonclinical or early clinical data support it — this is the 506(b) gate.
2. Propose the submission schedule. Once designated, submit a schedule for the sections still to come, typically organized around CMC, nonclinical, and clinical modules.
3. Get the schedule accepted. FDA reviews the proposed schedule under 506(c) and can decline to begin reviewing any submitted portion if the schedule is not acceptable — the designation alone does not compel FDA to start.
4. Pay the fee with the first portion. The applicable user fee becomes due when the first section is submitted, not when designation is granted.

Fast Track answers one question: does this drug have the potential to address an unmet need. Rolling Review answers a different one: can FDA actually review your application in the order you want to build it. Treating the first answer as settling the second is where submission timelines quietly slip. Why sponsors miscount the approvals needed

What this changes about submission planning

Sponsors building a NDA strategy around Fast Track often sequence their CMC, nonclinical, and clinical workstreams as if the designation alone determines when each can go in. It does not. The schedule FDA accepts under 506(c) is the actual pacing document, and FDA's discretion to find a schedule unacceptable means the submission plan needs to be realistic about section-completion dates before it is proposed — not aspirational. A sponsor that treats the Fast Track grant as the finish line, rather than the opening move in a second negotiation, is the one most likely to have a completed CMC section sitting unreviewed because the clinical section's timeline was never actually agreed with FDA.

None of this makes Fast Track less valuable — more frequent FDA interaction throughout development is a real benefit independent of Rolling Review. It does mean treating the two as one event is the planning mistake worth catching early, ideally before the first Type B meeting locks in a submission sequence the agency has not actually agreed to. For the broader set of expedited options and how they compare, see our accelerated pathways work.